论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Zhou S, Qiao J, Bai J, Wu Y, Fang H
Received 29 October 2017
Accepted for publication 6 December 2017
Published 24 January 2018 Volume 2018:14 Pages 167—171
DOI https://doi.org/10.2147/TCRM.S155488
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Hoa Le
Peer reviewer comments 2
Editor who approved publication: Professor Deyun Wang
Background: Biotherapy is becoming increasingly important in the treatment of
adult-onset Still’s disease (AOSD). The aim of our study was to evaluate the
efficacy and safety of biological therapy for AOSD resistant to traditional
therapy.
Patients and
methods: Database of Library of Congress, the
PubMed, and Web of Science Core Collection were used to retrieve relevant
articles published in English language until March 2017. Only studies published
in English language were included, and the additional references quoted in
these articles were also checked. Articles concerning the efficacy and safety
of all the biotherapies in refractory AOSD were evaluated.
Results: There were 112 articles available in total; 422 AOSD patients were given
at least one biologic. We found that 293 patients (69.43%) had received TNF-α
blocking agents (infiliximab, etanercept, and adalimumab), 194 patients
(45.97%) were treated with IL-1 receptor antagonists (anakinra, rilonacept, and
canakinumab), 163 patients (38.63%) were given IL-6 inhibitor (tocilizumab),
and 24 patients (5.69%) received rituximab and abatacept. The efficacy of
biological therapy and overall tolerance of biological therapy for refractory
AOSD were good. Thirty two of 271 patients given anti-TNF-α therapies (11.81%),
116 patients receiving IL-1 inhibitors (65.54%), 124 patients receiving
tocilizumab (76.07%), and 13 patients given other biological therapies (36.11%)
achieved remission. Side effects of biologic therapy were infections such as
urinary tract infections and soft tissue abscess.
Conclusion: Our findings suggest that anakinra and tocilizumab may be good choices
for the treatment of refractory AOSD considering the effectiveness and safety.
Keywords: adult-onset Still’s disease, biological therapy, treatment, side
effects, anakinra, toclizumab
摘要视频链接:Biological therapy for
adult-onset Still’s disease